VISCHER advised Polyneuron in its Series A Financing extension to CHF 36.5m

Polyneuron Pharmaceuticals, a clinical stage developer of a new class of antigen-specific polymers for the treatment of patients affected by autoimmune diseases, extended its Series A by CHF 14m bringing the total to CHF 36.5m. HBM Healthcare Investments joins as additional investor to lead investor Sofinnova Partners and New Enterprise Associates.

VISCHER advises Polyneuron with a team led by Matthias Staehelin (Partner – pictured) with Moritz Jäggy (Managing Associate), both Corporate.